BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...Inc. (NASDAQ:RYTM) on Oct. 5 as EVP and head of international. Mazabraud joins Rhythm from Trevi Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:AXLA) 5/8/19 $71.4 $459.8 $214.2 -53% Viva Biotech Holdings (HKEX:1873) 5/8/19 $193.9 $844.1 $693.0 -18% Trevi Therapeutics Inc....
...53%. Other poor first-day performers like cyclic peptide play Bicycle Therapeutics plc and itch company Trevi Therapeutics Inc....
...SIX:ROG; OTCQB:RHHBY), Basel, Switzerland Roivant Sciences GmbH, Basel, Switzerland Stoke Therapeutics Inc. (NASDAQ:STOK), Bedford, Mass. Trevi Therapeutics Inc....
BioCentury | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

...other biotechs -- diabetic cardiomyopathy and metabolic company Applied Therapeutics Inc. (NASDAQ:APLT) and pruritus company Trevi Therapeutics Inc....
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...to File for IPOs” ). Amid steep losses in the broader market Tuesday, pruritus company Trevi Therapeutics Inc....
BioCentury | May 8, 2019
Financial News

May 8 Financial Quick Takes: Trevi IPO, BMS, GeneQuantum

...Trevi prices $55M IPO below range Trevi Therapeutics Inc. (NASDAQ:TRVI) shares gained back some ground Wednesday -- adding...
...uses an enzyme-catalyzed intelligent continuous conjugation process. Brian Moy, Assistant Editor Bristol-Myers Squibb Co. GeneQuantum Healthcare (Suzhou) Co. Ltd. Trevi Therapeutics Inc....
BioCentury | Apr 8, 2019
Financial News

Itch company Trevi files for IPO

...a Phase IIb/III study of pruritus therapy nalbuphine ER scheduled to read out next year, Trevi Therapeutics Inc....
...OPRK1) - κ opioid receptor; MOR (OPRM1) - μ opioid receptor Paul Bonanos, Assistant Editor Nalbuphine ER (T111) Trevi Therapeutics Inc....
BioCentury | Jul 20, 2018
Company News

Management tracks: Merck KGaA, Aeglea

...at the Nemours Cardiac Center and the Alfred I. duPont Hospital for Children. Dermatology play Trevi Therapeutics Inc....
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...Jeanne Magram as CSO. She was CSO at Northern Biologics Inc. (Toronto, Ontario). Dermatology company Trevi Therapeutics Inc....
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...promoted Stephen Kennedy to COO and EVP. He had been chief technology officer. Dermatology play Trevi Therapeutics Inc....
BioCentury | Jul 21, 2017
Financial News

Trevi raises $50.5M in series C

...On July 20, dermatology play Trevi Therapeutics Inc. (New Haven, Conn.) raised $50.5 million in a series C...
...see BioCentury, Sept. 14, 2015 ). Trevi Therapeutics Inc. , New Haven, Conn. Mary Romeo T111 Menlo Therapeutics Inc. New Enterprise Associates Sanofi Trevi Therapeutics Inc. Kappa...
Items per page:
1 - 10 of 31
BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...Inc. (NASDAQ:RYTM) on Oct. 5 as EVP and head of international. Mazabraud joins Rhythm from Trevi Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:AXLA) 5/8/19 $71.4 $459.8 $214.2 -53% Viva Biotech Holdings (HKEX:1873) 5/8/19 $193.9 $844.1 $693.0 -18% Trevi Therapeutics Inc....
...53%. Other poor first-day performers like cyclic peptide play Bicycle Therapeutics plc and itch company Trevi Therapeutics Inc....
...SIX:ROG; OTCQB:RHHBY), Basel, Switzerland Roivant Sciences GmbH, Basel, Switzerland Stoke Therapeutics Inc. (NASDAQ:STOK), Bedford, Mass. Trevi Therapeutics Inc....
BioCentury | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

...other biotechs -- diabetic cardiomyopathy and metabolic company Applied Therapeutics Inc. (NASDAQ:APLT) and pruritus company Trevi Therapeutics Inc....
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...to File for IPOs” ). Amid steep losses in the broader market Tuesday, pruritus company Trevi Therapeutics Inc....
BioCentury | May 8, 2019
Financial News

May 8 Financial Quick Takes: Trevi IPO, BMS, GeneQuantum

...Trevi prices $55M IPO below range Trevi Therapeutics Inc. (NASDAQ:TRVI) shares gained back some ground Wednesday -- adding...
...uses an enzyme-catalyzed intelligent continuous conjugation process. Brian Moy, Assistant Editor Bristol-Myers Squibb Co. GeneQuantum Healthcare (Suzhou) Co. Ltd. Trevi Therapeutics Inc....
BioCentury | Apr 8, 2019
Financial News

Itch company Trevi files for IPO

...a Phase IIb/III study of pruritus therapy nalbuphine ER scheduled to read out next year, Trevi Therapeutics Inc....
...OPRK1) - κ opioid receptor; MOR (OPRM1) - μ opioid receptor Paul Bonanos, Assistant Editor Nalbuphine ER (T111) Trevi Therapeutics Inc....
BioCentury | Jul 20, 2018
Company News

Management tracks: Merck KGaA, Aeglea

...at the Nemours Cardiac Center and the Alfred I. duPont Hospital for Children. Dermatology play Trevi Therapeutics Inc....
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...Jeanne Magram as CSO. She was CSO at Northern Biologics Inc. (Toronto, Ontario). Dermatology company Trevi Therapeutics Inc....
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...promoted Stephen Kennedy to COO and EVP. He had been chief technology officer. Dermatology play Trevi Therapeutics Inc....
BioCentury | Jul 21, 2017
Financial News

Trevi raises $50.5M in series C

...On July 20, dermatology play Trevi Therapeutics Inc. (New Haven, Conn.) raised $50.5 million in a series C...
...see BioCentury, Sept. 14, 2015 ). Trevi Therapeutics Inc. , New Haven, Conn. Mary Romeo T111 Menlo Therapeutics Inc. New Enterprise Associates Sanofi Trevi Therapeutics Inc. Kappa...
Items per page:
1 - 10 of 31